pharma · Duchenne Muscular Dystrophy · Muscular Dystrophy, Duchenne · SRPT
Sarepta Therapeutics
Sarepta Therapeutics is a pharma organization headquartered in Cambridge, USA. It trades on NYSE under ticker SRPT. Primary therapeutic focus areas include Duchenne Muscular Dystrophy, Muscular Dystrophy, Duchenne, Duche
215 First Street, Cambridge, MA 02142, US HQ
1,150 Employees
Public company Type
SRPT · NYSE Ticker
Company details
- Status
- Public
- HQ
- 215 First Street, Cambridge, MA 02142, US
- Employees
- 1,150
- Programs
- 46
- Drugs
- 23
- Patents
- 102
Eteplirsen
Phase 3 · small molecule · Muscular Dystrophy, Duchenne
Eteplirsen for Muscular Dystrophy, Duchenne is a Phase 3 program (small_molecule) at Sarepta Therapeutics with 2 ClinicalTrials.gov record(s).
Internal code 4658-204
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Sarepta Therapeutics
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Muscular Dystrophy, Duchenne
- Status
- active
- Trials
- 2